Sanofi-Regeneron Cholesterol Drug Enters Late-Stage Trial

Sanofi and Regeneron Pharmaceuticals Inc. said they are enrolling patients in more than 10 late-stage clinical trials for a potentially first-in-class cholesterol-lowering drug targeting an enzyme called PCSK9.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.